Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs. Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.